

## Kininogen-1 Polyclonal Conjugated Antibody

Catalog No: #C42586



Package Size: #C42586-AF350 100ul #C42586-AF405 100ul #C42586-AF488 100ul  
 #C42586-AF555 100ul #C42586-AF594 100ul #C42586-AF647 100ul  
 #C42586-AF680 100ul #C42586-AF750 100ul #C42586-Biotin 100ul

Orders: [order@signalwayantibody.com](mailto:order@signalwayantibody.com)Support: [tech@signalwayantibody.com](mailto:tech@signalwayantibody.com)

## Description

Product Name	Kininogen-1 Polyclonal Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of total Kininogen-1 polyclonal antibody.
Immunogen Description	Recombinant human Kininogen-1 protein
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	Alpha-2-thiol proteinase inhibitor,Fitzgerald factor,High molecular weight kininogen,Williams-Fitzgerald-Flaujeac factor,KNG1,BDK, KNG
Accession No.	Swiss-Prot#:P01042
Uniprot	P01042
GeneID	3827;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	71
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

## Application Details

## Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250  
 AF405 conjugated: most applications: 1: 50 - 1: 250  
 AF488 conjugated: most applications: 1: 50 - 1: 250  
 AF555 conjugated: most applications: 1: 50 - 1: 250  
 AF594 conjugated: most applications: 1: 50 - 1: 250  
 AF647 conjugated: most applications: 1: 50 - 1: 250  
 AF680 conjugated: most applications: 1: 50 - 1: 250  
 AF750 conjugated: most applications: 1: 50 - 1: 250

## Background

---

Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

---

Note: This product is for in vitro research use only